Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, announced that Dr. Nirmal Kumar, their lead sericulture expert, has joined the production team at their new Southeast Asian rearing facility.
Dr. Kumar will oversee the first production cycle at the new center, focusing on BAM-1 spider silk production. His responsibilities include supervising the development of an expanded BAM-1 egg production center and testing lab. The company is also exploring partnerships with secondary processing providers and is in discussions with a potential customer regarding a custom spider silk thread order.
This development marks a significant step in Kraig Labs' transition to continuous production of their first recombinant spider silk hybrid line, positioning the company to meet growing market demand.
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has announced the successful transition of its production operations to two new rearing centers in a major Southeast Asian silk-producing region. The new facilities, operated by the Company's subsidiary Prodigy Silk, have already surpassed all previous years of production combined since the first center opened in early 2024.
The modern rearing centers combine advanced biotechnology with the region's established sericulture expertise, favorable climate, and infrastructure. The Company is completing the transfer of equipment from its original pilot facility, with completion expected by the end of August 2025. This strategic move represents a significant expansion milestone for Kraig Labs in commercializing spider silk technology.
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the full operational status of its second production rearing center in Southeast Asia. This expansion creates parallel operations with their existing facility, enabling continuous rearing cycles of specialized recombinant spider silk silkworms.
The new facility is working with BAM-1 production hybrids and three additional parental lines introduced in summer 2025. The dual-site strategy aims to eliminate previous production bottlenecks while increasing resilience and scalability. The expansion supports the company's commercialization strategy and strengthens their spider silk production platform.
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the launch of operations at its new production facility in Southeast Asia. The facility, established through a government agency collaboration, will begin its first full production cycle this week.
The site will produce the company's BAM-1 spider silk hybrid parent lines and several new transgenic strains introduced in early 2025. These next-generation strains are designed to deliver higher silk yields, improved quality, and enhanced robustness. The facility represents a strategic expansion of Kraig Labs' production capabilities as it prepares for anticipated product deliveries to potential customers.
Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a significant production milestone in spider silk manufacturing with the successful implementation of automated reeling equipment. The company processed over 250 kilograms of spider silk cocoons in a single run, setting a new record.
The automated system allows for precise control of reeling speeds and temperatures, optimizing fiber consistency and output. This advancement replaces conventional multi-end systems, improving throughput and labor efficiency. The achievement supports Kraig Labs' strategy of building a vertically integrated production model for spider silk at scale, complementing their recent expansion of rearing capacity in Asia and development of new spider silk strains.
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has signed a significant multi-year agreement with a Southeast Asian government agency to advance its spider silk production capabilities.
The collaboration provides Kraig Labs with access to government-supported rearing facilities, technical personnel, and infrastructure essential for scaling up production and expanding operational capacity. The company plans to initiate operations at the new facility in early August 2025.
This strategic partnership represents the culmination of years of groundwork and positions the company to accelerate its path toward large-scale commercialization of next-generation biomaterials.
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the successful completion of initial rearing cycles for three new recombinant spider silk production strains. The strains, recently transitioned from R&D to field production, have demonstrated excellent vitality and strong alignment with large-scale production targets.
The company is now focusing on expanding egg inventories through July and preparing for a second rearing cycle in early August. This achievement validates Kraig Labs' development pipeline and enhanced fiber engineering platform, marking a significant milestone in their strategy to deploy advanced spider silk genetics into operational production.
Kraig Biocraft Laboratories (OTCQB: KBLB) is finalizing a significant three-year collaboration agreement with a Southeast Asian government agency to expand its recombinant spider silk production. The agreement, expected to be signed by end of July 2025, will provide access to new rearing facilities, infrastructure, and technical resources.
The partnership aims to optimize and scale spider silk production through parallel rearing operations, eliminating single points of failure in the supply chain. The collaboration includes creating multiple independent facilities for parent strain and egg production, enhancing supply chain security and increasing throughput capacity. Work under this agreement is scheduled to begin in August 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced three major developments in its spider silk production capabilities. The company is adding a second parallel production facility in Southeast Asia, introducing three new advanced spider silk strains, and implementing a new diapausing system for production.
The new facility, expected to begin parental strain rearing within 30 days, will work in tandem with the existing facility to enable continuous production. The three new spider silk strains were designed to complement the existing BAM-1 hybrid, with two strains specifically bred for controlled diapause - a 90-day cold treatment process for premium silk production.
The company has completed its latest batch of BAM-1 finished spider silk, reaching approximately one-third of the total requirement for a globally renowned European fashion house. These developments aim to significantly increase production yields and spun silk quality while establishing a more resilient supply chain.